Results 251 to 260 of about 141,219 (262)
Some of the next articles are maybe not open access.
Primary amyloidosis (AL) in families
American Journal of Hematology, 1986AbstractWe report the occurrence of immunoglobulin‐related amyloidosis (AL) in three separate families, each family having two members affected. None of the six patients had evidence to suggest the presence of familial amyloidosis (AF). Previously, immunoglobulin‐related amyloidosis (AL) was considered to be a sporadic disease process.
Robert A. Kyle +2 more
openaire +2 more sources
Sudden Death by AL Amyloidosis
American Journal of Forensic Medicine & Pathology, 2023Abstract We report the case of a young female that died due to systemic amyloidosis.
Christian, Perez, Kristy, Waite
openaire +2 more sources
The epidemiology of AL and AA amyloidosis
Baillière's Clinical Rheumatology, 1994The limited available epidemiological information on AL amyloidosis suggests that there may be differences between population-based studies and case series data with respect to variables such as age and racial patterns. Much more work in this area is required before specific aetiologic hypotheses can be tested.
Robert W. Simms +2 more
openaire +3 more sources
Hematology/Oncology Clinics of North America, 2020
This article focuses on the patient experience of AL amyloidosis; the unique challenges that patients face from the journey to diagnosis through treatment; and management of this complex multisystemic disease. Included are descriptions of the most significant AL amyloidosis symptoms as well as addressing burden of disease, including financial concerns,
Mackenzie Boedicker, Isabelle Lousada
openaire +2 more sources
This article focuses on the patient experience of AL amyloidosis; the unique challenges that patients face from the journey to diagnosis through treatment; and management of this complex multisystemic disease. Included are descriptions of the most significant AL amyloidosis symptoms as well as addressing burden of disease, including financial concerns,
Mackenzie Boedicker, Isabelle Lousada
openaire +2 more sources
Immunomodulatory drugs in AL amyloidosis
Critical Reviews in Oncology/Hematology, 2016Immunoglobulin light chain amyloidosis (AL amyloidosis) is indeed a rare plasma cell disorder, yet the most common of the systemic amyloidoses. The choice of adequate treatment modality is complicated and depends dominantly on the risk stratification of these fragile patients.
Zuzana Kufova +2 more
openaire +3 more sources
Immune mechanisms of AL amyloidosis
Drug Discovery Today: Disease Mechanisms, 2004Light chain amyloidosis (AL) is both a disorder of protein conformation and a plasma cell dyscrasia, with secretion of altered light chains that polymerize systemically into amyloid fibrils leading to organ failure. Knowledge of the biological features of amyloid cells and of the mechanisms determining light chain organ targeting and cytotoxicity is ...
Perfetti V +2 more
openaire +2 more sources
Amyloidosis of pancreatic islets in primary amyloidosis (AL type)
Pathology International, 2005Seven cases of primary amyloidosis (AL‐type) were studied immunocytochemically for the possible involvement of pancreatic islets. The two cases with extensive organ involvement by AL‐amyloidosis revealed amyloid deposits in pancreatic islets by routine HE and Congo red staining, which were positive for amyloid p and amyloid a, but were only focally ...
openaire +3 more sources